Welcome to Targeted Radiopharmaceuticals (TRP) Summit, the industry-led forum designed to accelerate the development of next-generation radiopharmaceuticals. The faculty of expert speakers will lead us through a comprehensive discussion of the challenges and opportunities currently facing this space as it undergoes an exciting resurgence.
We have been working with companies including: Endocyte, MTR, Actinium Pharmaceuticals, Tagworks, Bayer and Roche, to assemble this agenda. The key focus of which will be exploring how to advance the therapeutic potential of radiation. The important role of diagnostic imaging is also key to providing a truly well-rounded conference in this field. As such, fully appreciating the potential that combinations of theranostics and diagnostics offer will be integral throughout.
The main areas of focus include:
- Identifying and Assessing the Therapeutic Potential of Novel Targets
- Updates on the New Regulatory Hurdles in the US and EU
- Optimising Chemical Modification Methods and Combination Rationale - Radioimmunotherapy and Beyond
Early booking and group discounts apply, start-up and academic rates are available - see the website for details.
Standard rate - Conference + 1 Workshop: EUR 3198.0
Standard rate - Conference Only: EUR 2699.0
Standard rate - Workshop Only: EUR 599.0
Start-up / Academic rate - Conference + 1 Workshop: EUR 1898.0
Start-up / Academic rate - Conference Only: EUR 1599.0
Start-up / Academic rate - Workshop Only: EUR 399.0
Speakers: Richard Baum, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Urs Hagemann, Laboratory Head, Bayer, Cristina Muller, Research Group Leader at Paul Scherrer Institute and Private Docent, ETH Zurich, Matt Harris, Chief Executive Officer, Clarity Pharmaceuticals, Greg Mullen, Chief Executive Officer, Theragnostics, Chris Leamon, Vice President of Research, Endocyte, Dale Ludwig, Chief Scientific Officer, Actinium Pharmaceuticals, Jostein Dahle, Chief Scientific Officer, Nordic Nanovector, Tony Lahoutte, Chief Scientific Officer, Camel-IDS, Christiane Smerling, Head of Nuclear Medicine and Imaging, 3B Pharmaceuticals, Marc Robillard, Chief Executive Officer, Tagworks Pharmaceuticals, Melpomeni Fani, Professor of Radiopharmaceutical Chemistry Research and Development, University Hospital of Basel, Marian Meckel, Research and Development Lead, ITG, Amal Saidi, Scientist, OranoMed, Chris Behrenbruch, Chief Executive Officer, Telix Pharmaceuticals, Daniel Stevens, Global Development Lead, IPSEN, Diane Chisholm, Head of Clinical Operations, Blue Earth Diagnostics, Izabela Tworowksa, Chief Scientific Officer, Radiomedix, Twan Lammers, Aachen University